Synthetic biology startup Synplogen and Ginkgo Bioworks have signed a non-binding memorandum of understanding to expedite DNA manufacture and gene therapy platform services in Japan.
The parties will seek business partnership prospects in DNA manufacturing on a global scale.
The OGAB DNA synthesis services of Synplogen have the potential to create DNA of varying lengths.
They can also carry out complex DNA synthesis with characteristics including repetitive sequences and a high/low guanine-cytosine concentration.
Synplogen will facilitate the launch of Ginkgo’s gene therapy services in Japan’s biotechnology and pharmaceutical ecosystem.
The company will provide business development and marketing support to extend Ginkgo’s services to enterprises in the sector.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
Ginkgo BioWorks co-founder and CEO Jason Kelly stated: “Japan has long been a leader in developing innovations for the bioeconomy.
“We’re thrilled to partner with Synplogen as we seek to grow our cell and gene therapy service offerings in Japan, as well as support the vibrant and innovative Japanese bioeconomy more broadly.”
The company is equipped to leverage its end-to-end AAV gene therapy development platform, along with its capabilities in high-throughput design and synthesis optimisation, to drive innovations in the Japanese bioeconomy.
Synplogen representative director and CEO Kazuhiko Yamamoto stated: “We are so honoured that our DNA synthesis technology has been recognised by Ginkgo Bioworks, which is the global biofoundry leader.
“Ginkgo’s services can play a crucial role in driving growth in Japan’s bioeconomy. We look forward to the practical impact of Ginkgo’s contributions, aligning well with our commitment to advancing innovative solutions for the Japanese biotech sector.”
In August 2023, Ginkgo BioWorks partnered with Merck (MSD) to enhance biologic manufacturing.
Ginkgo agreed to extend its cell engineering, protein characterisation, process streamlining and ultra-high-throughput multiplexed screening expertise to boost manufacturing efficiency and yields for biologics.
The company is entitled to receive $490m from MSD as part of the deal.
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.